Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 06:51 am Unchanged |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:08 pm Purchase |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 14.150% |
4,040,285 (+4.09%) |
Filing History |
| 2022-02-10 4:26 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 98,809,158 14.280% |
98,809,158 (New Position) |
Filing History |
| 2021-06-15 09:19 am Sale |
2021-06-14 | 13G | Protalix BioTherapeutics, Inc. PLX |
Dexcel Pharma Technologies Ltd. | 2,034,117 4.470% |
-2,521,914 (-55.35%) |
Filing History |
| 2021-02-16 12:06 pm Purchase |
2021-02-12 | 13G | Protalix BioTherapeutics, Inc. PLX |
Dexcel Pharma Technologies Ltd. | 4,556,031 10.300% |
1,267,940 (+38.56%) |
Filing History |